Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


4SC and Schwarz Pharma agree on long-term research cooperation

Martinsried, 05 April 2005 - 4SC AG, a drug discovery and development company specialising in research and development of therapeutic agents, announced today that they have made a research cooperation agreement with SCHWARZ PHARMA AG, Monheim. The aim is to identify a pre-development candidate for the prevention or therapy of a urological disorder.

This cooperation is the continuation of a pilot project in which 4SC was able to apply its proprietary virtual High Throughput Screening technology 4SCan® to identify and confirm hits for a disease relevant target structure defined by SCHWARZ PHARMA. The expansion of the cooperation serves to further develop the confirmed hits. 4SC will use its 4SCan® technology as well as medicinal chemical and biological expertise to develop suitable pharmaceutical leads to pre-development candidates.

As part of the agreement 4SC will receive research funds and is entitled to milestone payments. The deal also envisages that payments will be made when certain milestones in clinical development are reached as well as revenue share if the substance is brought to market successfully. Further details on the agreement remain undisclosed.

'We are delighted on Schwarz Pharma's decision to pursue this project with us,' commented Dr. Ulrich Dauer, 4SC's CEO. 'For our company, this cooperation clearly confirms our dual business model once more. The experience and financial means that our cooperation with the biopharmaceutical industry increases the growth potential of our business and contributes to our being able to develop our own projects efficiently.'

About 4SC
4SC is a drug discovery and development company that uses its cheminformatics-based technological platform for the discovery and development of new drug candidates. By combining the disciplines of chemistry and biology with the proprietary virtual High Throughput Screening technology, 4SCan®, the time and cost of advancing a drug candidate to the development phase can be significantly reduced.
The company|s therapeutic focus centres on infectious and hyperproliferative diseases. The clinical phase I studies for the agent SC12267 for treating autoimmune diseases such as rheumatoid arthritis or multiple sclerosis from 4SC's first clinical project were successfully completed. Additional research projects in the indications cancer, inflammation and bacterial infection are in research and pre-clinical development stages. 4SC, founded in 1997, currently employs 55 people and is based in Martinsried, near Munich, Germany.

SCHWARZ PHARMA AG (headquartered in Monheim, Germany) develops and markets innovative drugs for unmet medical needs with focus on neurology, urology and cardiovascular diseases. The company is investing in development projects targeting diseases such as Parkinson's disease, Restless Legs Syndrome, epilepsy, neuropathic pain and overactive bladder syndrome. The company has a strong international presence with subsidiaries in Europe, USA and Asia. Shares of SCHWARZ PHARMA AG are traded on the Frankfurt and Duesseldorf stock exchanges.

Publisher Contact Information:

+49 (0)89 700763

Company profile of 4SC AG
Past press releases of 4SC AG.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Dec 3€21.0MBusiness applications
Dec 2€7.0MDigital signal processing
Dec 2€7.4MBiotechnology
Nov 30€3.7MConsumer electronics
Nov 12€20.0MAgriculture related
Jan 17€13.0MArtificial Intelligence
Jan 10€18.5MBiopharmaceuticals

For information on Europe's most extensive database on technology funding click here!


Press Releases

Sep 30
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.